Site
Search results (Showing 1 - 10 of 15 results)
-
References | 17 Apr 2012
A case-control study of risk factors for multiple sclerosis in Iran.
-
References | 14 Apr 2015
Hypophosphatemia is Associated with the Serial Administration of Triple-Dose Gadolinium to Patients for Brain MRI.
Wolansky LJ, Cadavid D, Punia V, Kim S, Cheriyan J, Haghighi M, Cook SDJ Neuroimaging. 2015 Apr 13. PMID: 25867798. Abstract -
References | 31 Jul 2016
MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.
Brown RA, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L, Arnold DLNeurology. 2016 Jul 29. PMID: 27473139. Abstract -
References | 20 Jan 2010
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Chang P, Hamlett A, Musch B, et al.N Engl J Med. 2010 Feb 4; 362(5):416-26. Epub 2010 Jan 20. PMID: 20089960. Abstract -
References | 4 Dec 2012
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, et al.BMJ Open. 2012; 2(6). PMID: 23204140. Abstract -
References | 21 Dec 2012
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJJ Neurol. 2012 Dec 21. Epub 2012 Dec 21. PMID: 23263473. Abstract -
References | 15 Mar 2011
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY Study GroupLancet Neurol. 2011 Apr; 10(4):329-37. PMID: 21397565. Abstract -
References | 25 Oct 2011
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Greenberg S, et al.Clin Drug Investig. 2012 Jan 1; 32(1):15-27. PMID: 22017519. Abstract -
References | 5 Jun 2013
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
Hartung H-P, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, et al.JAMA Neurol. 2013 Jun 3:1-5. PMID: 23732754. Abstract -
References | 17 Mar 2013
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Lampl C, Nagl S, Arnason B, Comi G, O Connor P, Cook S, Jeffery D, Kappos L, Filippi M, Beckmann K, et al.J Neurol. 2013 Jul; 260(7):1838-45. Epub 2013 Mar 17. PMID: 23504050. Abstract